- Cassava Sciences press release ( NASDAQ: SAVA ): Q4 GAAP EPS of -$0.47 beats by $0.11 .
- At December 31, 2022, cash and cash equivalents were $201 million, compared to $233.4 million at December 31, 2021, with no debt. Year-end cash balance included net proceeds of $47.3 million from the sale of 1.7 million shares of common stock completed in November 2022.
- Net cash use for operations for the first half of 2023 is expected to be approximately $45 to $50 million, driven primarily by expenses for our clinical program in Alzheimer’s disease.
For further details see:
Cassava Sciences GAAP EPS of -$0.47 beats by $0.11